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BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to
poor prognosis. While sorafenib is the current recommended treatment for
advanced HCC, radioembolisation (RE; also called selective internal radiation
therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort
studies. However, there are no head-to-head trials comparing radiation therapy
with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has
been designed to compare the efficacy and safety of sorafenib therapy and RE using
yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North
Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-
effectiveness will also be compared between therapies.
METHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label,
multicentre trial comparing the efficacy of RE with sorafenib in the treatment of
patients with advanced HCC. The trial aims to recruit adults with a life expectancy
of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤
1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent
HCC after surgical or thermoablative treatment who are not eligible for surgical
resection, liver transplantation or thermal ablation; or two rounds of failed
chemoembolisation. Patients will be randomised 1:1 to receive either RE or
sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48
months following start of treatment. The primary endpoint of the SARAH trial is
overall survival (OS). Secondary endpoints include: adverse events, progression-
free survival at 6 months; tumour response rate; general or liver disease-specific
QoL scores; and cost of each treatment strategy. Assuming an increase in median
OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients
(200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha
risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients
due to ineligibility.
DISCUSSION: The SARAH trial is the first randomised head-to-head study to
compare RE with sorafenib in advanced HCC, and will establish the potential role of
RE in HCC treatment guidelines.
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